Crescent Biopharma (CBIO) Cash & Equivalents (2013 - 2026)
Crescent Biopharma (CBIO) reported Cash & Equivalents of $189.2 million for Q1 2026, up 743.39% year-over-year from $22.4 million in Q1 2025, and down 11.27% on a QoQ basis from $213.2 million in Q4 2025.
Crescent Biopharma (CBIO) has 14 years of Cash & Equivalents data on file, last reported at $189.2 million in Q1 2026.
- Quarterly Cash & Equivalents rose 743.39% year-over-year to $189.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $189.2 million (up 743.39% YoY) and the FY2025 annual result came in at $213.2 million, up 513.22% from the prior year.
- Cash & Equivalents eased to $189.2 million in Q1 2026 per CBIO's latest filing, from $213.2 million in the prior quarter.
- Across five years, Cash & Equivalents topped out at $213.2 million in Q4 2025 and bottomed at $14.4 million in Q3 2024.
- The 5-year median for Cash & Equivalents is $50.5 million (2022), against an average of $69.5 million.
- The widest annual swing landed in 2024, when Cash & Equivalents sank 70.85%; it then soared 825.45% in 2025.
- Tracing CBIO's Cash & Equivalents over 5 years: stood at $47.9 million in 2022, then declined by 12.7% to $41.8 million in 2023, then dropped by 16.81% to $34.8 million in 2024, then surged by 513.22% to $213.2 million in 2025, then dropped by 11.27% to $189.2 million in 2026.
- Per Business Quant, the three latest CBIO Cash & Equivalents figures stand at $189.2 million (Q1 2026), $213.2 million (Q4 2025), and $133.3 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 1.91 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | 32.30 Mn |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 286.70 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | 61.46 Mn |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 2.77 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 5.49 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | 18.44 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 2.96 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 1.71 Bn |
| 10 | Crescent Biopharma | 569.36 Mn | 380.20 Mn | - | 189.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 189.16 Mn |
| Dec 31, 2025 | 213.19 Mn |
| Sep 30, 2025 | 133.27 Mn |
| Mar 31, 2025 | 22.43 Mn |
| Dec 31, 2024 | 34.77 Mn |
| Sep 30, 2024 | 14.40 Mn |
| Jun 30, 2024 | 22.40 Mn |
| Mar 31, 2024 | 31.28 Mn |
| Dec 31, 2023 | 41.79 Mn |
| Sep 30, 2023 | 49.41 Mn |
| Jun 30, 2023 | 58.04 Mn |
| Mar 31, 2023 | 65.00 Mn |
| Dec 31, 2022 | 47.87 Mn |
| Sep 30, 2022 | 51.60 Mn |
| Jun 30, 2022 | 60.20 Mn |
| Mar 31, 2022 | 76.52 Mn |
| Dec 31, 2021 | 90.25 Mn |
| Sep 30, 2021 | 101.92 Mn |
| Jun 30, 2021 | 118.85 Mn |
| Mar 31, 2021 | 132.47 Mn |
| Dec 31, 2020 | 137.04 Mn |
| Sep 30, 2020 | 142.87 Mn |
| Mar 31, 2020 | 154.82 Mn |
| Dec 31, 2019 | 158.20 Mn |
| Sep 30, 2019 | 170.89 Mn |
| Jun 30, 2019 | 184.17 Mn |
| Mar 31, 2019 | 195.56 Mn |
| Dec 31, 2018 | 209.92 Mn |
| Sep 30, 2018 | 219.83 Mn |
| Jun 30, 2018 | 229.43 Mn |
| Mar 31, 2018 | 242.63 Mn |
| Dec 31, 2017 | 123.92 Mn |
| Sep 30, 2017 | 112.87 Mn |
| Jun 30, 2017 | 119.15 Mn |
| Mar 31, 2017 | 34.59 Mn |
| Dec 31, 2016 | 40.04 Mn |
| Sep 30, 2016 | 45.28 Mn |
| Jun 30, 2016 | 53.09 Mn |
| Mar 31, 2016 | 38.83 Mn |
| Dec 31, 2015 | 46.80 Mn |
| Sep 30, 2015 | 53.76 Mn |
| Jun 30, 2015 | 40.23 Mn |
| Mar 31, 2015 | 46.57 Mn |
| Dec 31, 2014 | 55.20 Mn |
| Sep 30, 2014 | 61.36 Mn |
| Jun 30, 2014 | 66.22 Mn |
| Mar 31, 2014 | 56.97 Mn |
| Dec 31, 2013 | 2.31 Mn |
| Sep 30, 2013 | 7.69 Mn |
| Jun 30, 2013 | 10.78 Mn |
| Mar 31, 2013 | 13.49 Mn |